Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2004
Business Overview: Alnylam is a biopharmaceutical company developing RNA interference (RNAi) therapeutics. During the quarter ended June 30, 2004, the Company emerged from the development stage as collaboration research activities became significant. In June 2004, the Company completed its Initial Public Offering (IPO), selling 5.75 million shares at $6.00 per share for net proceeds of $30.0 million.
Key Financial Metrics
| Metric ($ in thousands) | Six Months Ended June 30, 2004 |
Six Months Ended June 30, 2003 |
|---|---|---|
| Revenue | $265 | $0 |
| Net Loss | $(20,538) | $(5,394) |
| Net Loss Attributable to Common Stockholders | $(23,251) | $(6,264) |
| Net Loss Per Share (Basic & Diluted) | $(5.39) | $(12.52) |
| Cash and Cash Equivalents (End of Period) | $31,891 | $10,898 |
| Total Assets | $68,473 | $35,183 |
| Total Liabilities | $17,798 | $6,701 |
| Accumulated Deficit | $(50,889) | $(29,518) |
Liquidity: As of June 30, 2004, the Company held $31.9 million in cash and cash equivalents and $14.2 million in marketable securities. The Company has an equipment line of credit with Lighthouse Capital Partners for up to $10.0 million, with $5.7 million drawn as of the reporting date.
Material Changes vs. Prior Period
- Revenue Recognition: The Company recognized $265,000 in revenue from research collaborators for the six months ended June 30, 2004, compared to zero in the prior year. This stems from deferred revenue recognition related to a collaboration with Merck.
- Operating Expenses: Total operating costs and expenses increased to $20.6 million from $5.4 million year-over-year.
- R&D Expenses: Rose to $14.6 million from $3.1 million. Increases were driven by a $5.0 million license fee paid to Isis Pharmaceuticals, expenses from the acquired Alnylam Europe entity, and increased payroll.
- G&A Expenses: Rose to $6.0 million from $2.4 million due to increased stock-based compensation, Alnylam Europe integration costs, and hiring.
- Financing Activities: Net cash provided by financing activities was $44.3 million, primarily due to the $30.0 million IPO proceeds and $10.0 million from the issuance of Series D preferred stock (later converted to common stock).
- Capital Structure: All redeemable convertible preferred stock was converted to common stock upon the closing of the IPO in June 2004. Consequently, accretion charges on preferred stock will cease after this period.
Outlook, Risks, and Management Commentary
Strategic Collaborations:
- Merck: Entered a new multi-year collaboration in June 2004 to develop RNAi therapeutics for ocular diseases (specifically Age-Related Macular Degeneration). Alnylam received a $2.0 million license fee and $1.0 million in R&D reimbursement, both deferred and recognized over time. Potential cash milestones total $19.5 million.
- Isis Pharmaceuticals: Entered a collaboration in March 2004. Alnylam paid a $5.0 million upfront license fee ($3.0 million paid, $2.0 million due Jan 2005) and agreed to milestone payments totaling $3.4 million.
Liquidity and Capital Needs: Management believes current resources, including IPO proceeds, are sufficient to fund operations through at least the end of 2005. However, the Company expects to incur significant additional losses and will require substantial additional funds for clinical trials and commercialization. Future funding may come from equity offerings, debt, or collaborations.
Key Risks:
- Technology Risk: RNAi is an unproven therapeutic approach; no RNAi therapeutics have received regulatory approval. Success depends on overcoming delivery and stability challenges.
- Regulatory Risk: The FDA has not established definitive policies for RNAi drugs, creating uncertainty in the approval timeline and requirements.
- Intellectual Property: The Company relies on third-party licenses (e.g., Isis, Max Planck). A key patent (Kreutzer-Limmer) is subject to opposition proceedings in Europe which could result in invalidation.
- Dependence on Collaborators: The Company lacks sales, marketing, and manufacturing capabilities and relies heavily on partners like Merck for commercialization and funding.
Investor Verification Checklist
- Runway: Verify if the $46.0 million in liquid assets (cash + marketable securities) is sufficient to sustain the projected burn rate through 2005 without additional dilution.
- Revenue Recognition: Confirm the timeline for recognizing the deferred revenue from the Merck collaboration ($3.0 million total) and the impact on future earnings.
- Isis License Fee: Monitor the payment of the remaining $2.0 million license fee due to Isis in January 2005 and the associated cash flow impact.
- Patent Status: Track the outcome of the European Patent Office opposition proceedings regarding the Kreutzer-Limmer patent, which is critical to the Company's IP portfolio.
- Clinical Progress: Verify the timeline for initiating the clinical trial for the Age-Related Macular Degeneration (AMD) product candidate, currently expected in the second half of 2005.